Endocrine Therapy of Estrogen Receptor-Positive Breast Cancer Cells: Early Differential Effects on Stem Cell Markers.

ABSTRACT:

Introduction

Endocrine therapy of breast cancer, which either deprives cancer tissue of estrogen or prevents estrogen pathway signaling, is the most common treatment after surgery and radiotherapy. We have previously shown for the estrogen-responsive MCF-7 cell line that exposure to tamoxifen, or deprivation of estrogen, leads initially to inhibition of cell proliferation, followed after several months by the emergence of resistant sub-lines that are phenotypically different from the parental line. We examined the early responses of MCF-7 cells following either exposure to 4-hydroxytamoxifen or deprivation of estrogen for periods of 2 days-4 weeks.

Methods

Endocrine-sensitive or -resistant breast cancer cell lines were used to examine the expression of the stem cell gene

SUBMITTER: Leung EY 

PROVIDER: S-EPMC5591432 | biostudies-literature | 2017

REPOSITORIES: biostudies-literature